| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | HAP; RRB2; NR1B2 |
| WB Predicted band size | 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human RARB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于EDNRA抗体的模拟参考文献示例(仅供参考，实际文献请通过学术数据库查询)：
---
1. **文献名称**：*EDNRA Antibody Targeting in Melanoma: Expression and Therapeutic Implications*
**作者**：Smith, J. et al.
**摘要**：本研究使用特异性EDNRA抗体检测黑色素瘤组织中内皮素受体A(EDNRA)的过表达，发现其与肿瘤血管生成和转移相关。实验表明，EDNRA抗体可抑制肿瘤细胞迁移，提示其作为潜在治疗靶点的价值。
2. **文献名称**：*Development of a High-Affinity EDNRA Monoclonal Antibody for Cardiovascular Research*
**作者**：Lee, H. & Zhang, Y.
**摘要**：研究团队开发了一种高亲和力EDNRA单克隆抗体，用于检测动脉粥样硬化模型中EDNRA的动态表达。该抗体在体外实验中有效阻断内皮素-1介导的血管收缩，为心血管疾病机制研究提供了新工具。
3. **文献名称**：*EDNRA as a Biomarker in Prostate Cancer: Validation via Immunohistochemical Staining*
**作者**：Garcia, R. et al.
**摘要**：通过EDNRA抗体进行免疫组化分析，发现前列腺癌组织中EDNRA表达水平与疾病进展呈正相关。研究提示EDNRA可作为预后标志物，并为抗体介导的靶向治疗提供依据。
4. **文献名称**：*Preclinical Evaluation of EDNRA-Neutralizing Antibody in Pulmonary Hypertension Models*
**作者**：Wang, L. et al.
**摘要**：在肺动脉高压动物模型中，EDNRA中和抗体显著降低右心室收缩压和肺血管重塑，证实其通过抑制EDNRA信号通路改善病理表型，支持进一步临床转化研究。
---
**注意**：以上为模拟生成的参考文献，实际研究需通过PubMed、Google Scholar等平台检索关键词(如"EDNRA antibody"、"endothelin receptor A therapeutic")。
The endothelin receptor type A (EDNRA) is a G protein-coupled receptor (GPCR) that binds endothelin-1 (ET-1), a potent vasoconstrictor peptide involved in cardiovascular homeostasis, cell proliferation, and tissue remodeling. EDNRA is primarily expressed in vascular smooth muscle cells, where it mediates vasoconstriction, inflammation, and fibrosis by activating signaling pathways such as phospholipase C and mitogen-activated protein kinase (MAPK). Dysregulation of EDNRA signaling has been implicated in hypertension, pulmonary arterial hypertension (PAH), cancer progression, and fibrotic diseases.
EDNRA antibodies are tools designed to detect, quantify, or inhibit this receptor in research and clinical contexts. In research, they aid in studying receptor localization, expression levels, and signaling mechanisms using techniques like immunohistochemistry, Western blotting, and flow cytometry. Therapeutically, EDNRA-targeting monoclonal antibodies or small-molecule antagonists (e.g., ambrisentan) have been explored to block pathogenic ET-1/EDNRA interactions, particularly in PAH and cancers where EDNRA overexpression correlates with tumor angiogenesis, metastasis, and poor prognosis.
Developing selective EDNRA antibodies remains challenging due to structural similarities with the endothelin receptor type B (EDNRB). However, advances in epitope mapping and antibody engineering have improved specificity, enabling more precise modulation of EDNRA for potential diagnostic and therapeutic applications.
×
